Key clinical point:
Major finding: The prodrug reduced LDL cholesterol levels by 15%, compared with a 2.4% increase in the placebo group.
Study details: CLEAR Wisdom, a 52-week placebo-controlled study in 2,300 patients.
Disclosures: This study was funded by Esperion Therapeutics. Dr Goldberg reported receiving research grants/support from Amgen, Amarin, Pfizer, Regeneron, Sanofi, IONIS, Novartis, and Merck and serving as a consultant for Esperion, Novartis, Akcea, OptumRX, 23andMe, Sanofi/Regeneron, and Merck.
Goldberg AC et al..